×
ADVERTISEMENT

OCTOBER 26, 2023

FDA Approves Tibsovo for Myelodysplastic Syndromes


Originally published by our sister publication Clinical Oncology News

The FDA approved ivosidenib (Tibsovo, Servier Pharmaceuticals) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test.